GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tasly Pharmaceutical Group Co Ltd (SHSE:600535) » Definitions » ROIC %

Tasly Pharmaceutical Group Co (SHSE:600535) ROIC % : 11.23% (As of Mar. 2024)


View and export this data going back to 2002. Start your Free Trial

What is Tasly Pharmaceutical Group Co ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Tasly Pharmaceutical Group Co's annualized return on invested capital (ROIC %) for the quarter that ended in Mar. 2024 was 11.23%.

As of today (2024-05-03), Tasly Pharmaceutical Group Co's WACC % is 10.86%. Tasly Pharmaceutical Group Co's ROIC % is 10.99% (calculated using TTM income statement data). Tasly Pharmaceutical Group Co generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Tasly Pharmaceutical Group Co ROIC % Historical Data

The historical data trend for Tasly Pharmaceutical Group Co's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tasly Pharmaceutical Group Co ROIC % Chart

Tasly Pharmaceutical Group Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.30 7.16 9.19 25.11 11.41

Tasly Pharmaceutical Group Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.96 14.95 12.22 5.74 11.23

Competitive Comparison of Tasly Pharmaceutical Group Co's ROIC %

For the Drug Manufacturers - Specialty & Generic subindustry, Tasly Pharmaceutical Group Co's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tasly Pharmaceutical Group Co's ROIC % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tasly Pharmaceutical Group Co's ROIC % distribution charts can be found below:

* The bar in red indicates where Tasly Pharmaceutical Group Co's ROIC % falls into.



Tasly Pharmaceutical Group Co ROIC % Calculation

Tasly Pharmaceutical Group Co's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROIC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=1504.805 * ( 1 - 16.74% )/( (10961.091 + 11006.43)/ 2 )
=1252.900643/10983.7605
=11.41 %

where

Invested Capital(A: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=16476.914 - 1271.509 - ( 4244.314 - max(0, 2147.215 - 9260.211+4244.314))
=10961.091

Invested Capital(A: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=16714.285 - 956.546 - ( 4751.309 - max(0, 2369.556 - 8732.681+4751.309))
=11006.43

Tasly Pharmaceutical Group Co's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Mar. 2024 is calculated as:

ROIC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=1589.712 * ( 1 - 21.74% )/( (11006.43 + 11151.828)/ 2 )
=1244.1086112/11079.129
=11.23 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=16714.285 - 956.546 - ( 4751.309 - max(0, 2369.556 - 8732.681+4751.309))
=11006.43

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=17517.01 - 1506.318 - ( 4858.864 - max(0, 2852.78 - 9573.84+4858.864))
=11151.828

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tasly Pharmaceutical Group Co  (SHSE:600535) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Tasly Pharmaceutical Group Co's WACC % is 10.86%. Tasly Pharmaceutical Group Co's ROIC % is 10.99% (calculated using TTM income statement data). Tasly Pharmaceutical Group Co generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases. Tasly Pharmaceutical Group Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Tasly Pharmaceutical Group Co ROIC % Related Terms

Thank you for viewing the detailed overview of Tasly Pharmaceutical Group Co's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Tasly Pharmaceutical Group Co (SHSE:600535) Business Description

Traded in Other Exchanges
N/A
Address
2 Pujihe Road East, Beichen District, Tasly TCM Garden, Tianjin, CHN, 300410
Tasly Pharmaceutical Group Co Ltd is a China-based company engaged in the manufacturing and distribution of pharmaceutical products. Its herbal medicines include Tasly Cerebral Care Granules and Tasly ICP. Its chemical medicines comprise of Ketotifen Fumarate Tablets, Thiamphenicol Capsules, Glucurolactone Tablets and Sulpiride Tablets. Some of the other products offered by the company include PharmceuticalSubstances & API, HerbalExtract, and Concentrated Herbal Granules.

Tasly Pharmaceutical Group Co (SHSE:600535) Headlines

No Headlines